department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Briumvi · pharmadog

pharmadog
drugs
Briumvi

drug

patient view →

ublituximab

Marketedupdated 2mo ago

by $TGTX TG THERAPEUTICS, INC.

Approved

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.

all catalysts(5)

approval · 5

BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval

BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval

BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval

BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval

BRIUMVI (UBLITUXIMAB-XIIY) — FDA approval

News(0)

no news has mentioned this drug yet

brand

Briumvi

generic

ublituximab

MOA

12.1 Mechanism of Action The precise mechanism by which ublituximab-xiiy exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ublituximab-xiiy results in cell lysis through mechanisms including antibody-dependent cellular cytolysis and complement-dependent cytolysis.

indication

Relapsing Multiple Sclerosis (RMS)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$TGTX55.25+3.64%

$TGTX55.25+3.64%

$TGTX55.25+3.64%

$TGTX55.25+3.64%

$TGTX55.25+3.64%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagApproval20 co-mentions · 5 sources
drugBRIUMVI20 co-mentions · 5 sources
company$TGTXTG THERAPEUTICS, INC.10 co-mentions · 5 sources

Trials studying ublituximab

phase3An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosisactive not recruitingn=1,100
phase3Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximabrecruitingn=800
phase3Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosisnot yet recruitingn=240
phase4Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosisrecruitingn=50
phase2Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathyrecruitingn=30
phase3A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)recruitingn=360
phase2A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)not yet recruitingn=350
N/AExploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosisnot yet recruitingn=30

more trials →